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Case Report
Vertical Transmission of SARS-CoV-2 in a Twin
Pregnancy
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Transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first identified in 2019 and rapidly evolved into the global coronavirus disease 2019
(COVID-19) pandemic. The emergence of a highly morbid disease has posed ongoing challenges in the diagnosis, management, and prevention of COVID-19. The uncertainty underlying medical decision making is further compounded by preexisting conditions, including
pregnancy. Here, we report a twin pregnancy complicated by maternal COVID-19 and the
vertical transmission of SARS-CoV-2. We hope that our experiences contribute to a better
understanding of the disease in pregnancy and, ultimately, guide the development of effective treatment and prevention strategies.
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Background

The normal cardiopulmonary and immune
system changes of pregnancy increase susceptibility to infection, including the severe acute
respiratory syndrome coronavirus 2 (SARSCoV-2 virus).1 The first and third trimesters of
pregnancy are associated with a shift towards a
pro-inflammatory environment,2 which may be
further induced by the cytokine-storm associated with coronavirus disease 2019 (COVID-19).1
Pregnant women diagnosed with COVID-19 are
at increased risk of preterm delivery and stillbirth.3,4 These recent findings are compounded
by the potential for vertical transmission to the
neonate. There are limited and conflicting data
on vertical transmission. Some studies report
no evidence of vertical transmission, despite
thorough analysis of placental pathology, cord
blood serology, and culture of amniotic fluid.5
However, a systematic review of 38 studies
found potential vertical transmission in 3.2% of

infected mothers in the third trimester, with
the earliest positive test of a newborn at 16
hours of life.6 Proposed mechanisms of vertical transmission include the direct infection of
syncytiotrophoblasts, a passage from the maternal circulation to extravillous trophoblasts,
a passage through maternal immune cells, and
an ascending vaginal infection.7
In this report, we present a case of maternal
COVID-19 infection with monochorionic-diamniotic twin gestation in Louisiana and subsequent neonatal COVID-19 infection confirmed
in both twins at 24 hours of life.

Case Presentation

In November 2020, a 22-year-old primiparous
female with an uncomplicated monochorionic-diamniotic twin pregnancy at 27 weeks and
1 day of gestational age presented to labor
and delivery triage with symptoms concerning for COVID-19. Prior to this presentation,
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the patient received regular prenatal care and
had traveled over 200 miles to visit family
when her symptoms began. Outside prenatal
records were requested, but due to the acute
and fulminant clinical course, the records were
not available. She reported a 4-day history of
exertional dyspnea, headache, and myalgias.
These symptoms initially improved with acetaminophen, guaifenesin, and diphenhydramine.
Forty-eight hours after the initial onset of
symptoms, she had a positive COVID-19 test
result. After an additional 48 hours, she noted
persistent fever, prompting evaluation in labor
and delivery. She denied obstetric complaints,
including contractions, vaginal bleeding, decreased fetal movement, or leaking of fluid.
She reported a history of asthma, last requiring an albuterol inhaler over 5 years ago. Her
previous gynecologic, surgical, family, and social
histories were unremarkable.
On arrival, she was febrile to 100.9 °F, tachycardic to 135 bpm, but normotensive. Oxygen
saturation initially remained at 96-99% without
the use of supplemental oxygen. She appeared
mildly dyspneic with conversation. The remainder of the physical examination was unremarkable, including lung spaces that were clear to
auscultation. Initial chest radiograph showed
bibasilar patchy lung opacities concerning
for early airspace disease (Figure 1). Maternal
laboratory results are presented in Table 1.
Laboratory testing revealed a mildly elevated
aspartate aminotransferase, lymphopenia, and
an elevated erythrocyte sedimentation rate,
a prothrombin time of 9.3 seconds, and an
activated partial thromboplastin time of 32.3
seconds. Urinalysis was unremarkable.

External fetal heart rate monitoring showed
both twins had fetal tachycardia with a baseline in the range of 190-200 bpm, moderate
variability, and intermittent variable and late
decelerations. External uterine tocodynamometer showed uterine contractions every 1-2
minutes that resolved with intravenous fluid
resuscitation. The patient was admitted for
symptomatic management of COVID-19 and
continuous fetal monitoring.
Approximately 3 hours after arrival, there was
an abrupt onset change in the fetal status of
both twins. Twin A had recurrent late decelerations with a decrease in variability, followed
by prolonged fetal heart rate deceleration
that was refractory to in-utero resuscitation
methods. Twin B‘s fetal heart rate could not be
traced continuously as a loss of signal was noted. However, late decelerations were evident.
Due to the non-reassuring fetal heart rate
tracing for both twins, the decision was made
to proceed with an emergent cesarean delivery.
She delivered viable twin female infants weighing 940g and 730g, respectively. Twin A had
APGAR scores of 1 at 1 minute, 3 at 5 minutes,
and 4 at 10 minutes. Twin B had APGAR scores
of 2 at 1 minute and 7 at 5 minutes (Table 2).
Placental pathology was notable for focal acute
chorioamnionitis of the fetal membranes and a
slightly increased perivillous fibrin deposition.
Both infants were immediately handed off to
the Neonatal intensive care unit (NICU). Neonatal statuses at delivery are presented in Table
2. Both twins were intubated and admitted to
the NICU for respiratory distress syndrome and
nutritional support. Both neonates tested positive for COVID-19 at 24 hours, 48 hours, and

Figure 1. Posteroanterior and lateral radiographs of the patient’s chest on the day of presentation
show bilateral airspace opacities.
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Table 1. Maternal Laboratory Data
On admission
Laboratory test

Day 1

Day 2

Day 3

Day 4

Reference range

5.3

5.7

4.4*

5.2

4.5 – 11.0

Hematology
White blood cell count, K/μL
Hemoglobin, g/dL

12.4

10.1*

10.7*

11.0*

12.0 – 16.0

Hematocrit, %

38.5

31.0*

33.9*

35.1*

36.0 – 46.0

Mean corpuscular volume, fL

85.4

85.6

87.4

86.7

80.0 – 100.0

Mean corpuscular hemoglobin concentration, g/dL

32.2

32.6

31.6*

31.3*

32.0 – 35.0

Red cell distribution width, %

16.2*

16.1*

16.9*

17.1*

12.0 – 15.0
160 – 420

Platelet count, K/μL

199

170

175

214

Absolute Gran

0.10

0.08

0.06

0.07

Immature Gran, %

1.9

1.4

1.4

1.4

0–3

Neutrophils, %

87*

81*

59

51*

52 – 70

Lymphocytes, %

6*

10*

30

39

20 – 44

Monocytes, %

5

8

8

8

0 – 10

Eosinophils %

0

0

1

1

1–5

Basophils, %

0

0

1

0

0–2

Erythrocyte sedimentation rate, mm/hr

27*

---

---

---

0 – 20

Chemistry
Sodium, mmol/L

134

134

139

140

134 – 144

Potassium, mmol/L

4.0

3.9

3.9

3.8

3.6 – 5.2

Chloride, mmol/L

100

102

107

108

96 – 107

Carbon dioxide, mmol/L

26

25

28

26

21 – 32

Urea nitrogen, mg/dL

4

7

10

10

5 – 23

Creatinine, mg/dL

0.7

0.7

0.7

0.6

0.6 – 1.0

Glomerular filtration rate

111

111

111

132

Glucose, mg/dL

72

90

72

68

68 – 106

Lactic acid, mmol/L

1.5

---

---

---

0.67 – 2.47

Uric acid, mg/dL

4.4

---

---

---

3.0 – 5.8

Calcium, mg/dL

9.3

7.8

8.3*

8.4

8.4 – 10.4

Phosphorus, mg/dL

3.7

4.8*

---

---

2.5 – 4.2

Magnesium, mg/dL

1.5*

---

---

---

1.6 – 2.5

Ferritin, μ/L

---

---

127

---

8 – 252

Total bilirubin, mg/dL

0.3

0.2

0.2

0.3

<1.1

Direct bilirubin, mg/dL

---

0.1

0.1

---

<0.4

Aspartate aminotransferase, U/L

46*

135*

117*

84*

<35

Alanine aminotransferase, U/L

46*

60*

74*

63*

30 – 65

Alkaline phosphatase, U/L

105

66

55

58

40 – 120

Lactate dehydrogenase, U/L

220

---

---

---

81 – 234

Troponin I, ng/mL

<0.017

---

---

---

0.000 – 0.056

N-terminal pro-B-type natriuretic peptide, pg/mL

129

---

---

---

0 – 450

Total protein, g/dL

6.8

5.1

5.3

5.6

6.3 – 8.2

Albumin, g/dL

2.7*

1.9*

2.0*

2.1*

3.4 – 5.0

Albumin/Globulin ratio

0.6

---

0.6

0.6

9.3*

---

---

---

Coagulation
Prothrombin time, sec

9.5 – 12.0

International normalized ratio

0.91

---

---

---

0.9 – 1.1

Activated partial thromboplastin time, sec

32.3*

---

---

---

21.0 – 32.0

Fibrinogen, mg/dL

512*

---

---

---

168 – 404

D-dimer, mg/mL

---

6.41*

---

---

0 – 0.59

*Indicates abnormal result.
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Table 2. Neonate Findings
Variable

Twin A

Twin B

Sex

Female

Female

Birth weight, g

940

730

Birth weight percentile, %

55.2

17.9

APGARs at 1, 5, and 10 min

1, 3, 4

2,7

Presentation

Cephalic

Breech

Temperature, °F

99.5

102.9

Heart rate, beats/min

173

192

Respiratory rate, respirations/min

75

65

Blood pressure, mmHg

45/44

43/26

White blood cell count, K/μL

14.6

11.7

Hemoglobin, g/dL

13.7

13.5

Hematocrit, %

42.2

40.6

Platelet count, K/μL

160

159

Sample site

Arterial line

Arterial line

pH

7.168*

7.249

pCO2

58.3*

44.3

pO2

33.4*

45.1*

HCO3-

21.2

19.4

Base excess

-8.0*

-7.7*

FiO2

60

30

O2 saturation

67.0

27

PO2/FiO2 ratio

55.6*

150.3*

Length of stay, days

7*

88*

Birth

Vital signs

Laboratory data

Arterial blood gases

*Indicates abnormal result

day 8 of life through a nasopharyngeal swab.
On day 8, twin A passed away from pseudomonas sepsis. Twin B was discharged to home in
stable condition at 88 days old.
After delivery, on postoperative day 1, the patient developed shortness of breath and hypoxemia, requiring supplemental oxygen at a rate
of 3 liters per minute to maintain her oxygen
saturation above 94%. Due to persistent symptoms, the patient received intravenous 6 mg of
dexamethasone daily until hospital discharge
on postoperative day 3. Persistent radiographic
evidence of respiratory disease was demonstrated on sequential chest radiographs. The
patient declined the use of intravenous remde-
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sivir therapy. Her serum D-dimer level was noted to be elevated in the absence of symptoms
suspicious of venous thromboembolism or a
personal history of thrombosis. However, due
to multiple obstetrics risk factors, including
recent cesarean delivery of a preterm multifetal gestation pregnancy, and ongoing systemic
infection with COVID-19 requiring hospitalization, thromboprophylaxis with unfractionated
heparin was initiated. On postoperative day
2 (hospital day 3), her respiratory status improved, no longer requiring supplemental oxygen, which was subsequently discontinued, and
adequate oxygenation was maintained on room
air. By postoperative day 3 (hospital day 4), she
met all milestones and was discharged home.

Chang et al. (2022) 3:6. https://doi.org/10.36518/2689-0216.1371

Discussion

These findings highlight the risk of preterm
delivery due to fetal distress and neonatal
SARS-CoV-2 infection in a pregnancy complicated by maternal COVID-19. Pregnant women
infected with SARS-CoV-2 are known to be at
increased risk of cesarean delivery and preterm
delivery, as in this case.9 The increased risk of
preterm birth is most strongly associated with
active infection during the third trimester, and
future studies may need to investigate whether
adverse early trimester outcomes are increased
in patients who have preexisting risk factors for
preterm delivery, such as the multiple gestation seen in this patient.9-12
While other studies at the time of this case
have shown most infants born to mothers
infected with SARS-CoV-2 do not have detectable levels of viral RNA in the nasopharynx
or other COVID-19 signs and symptoms, our
case of SARS-CoV-2 infection in twin neonates
indicate the potential for vertical transmission
in a mother with COVID-19. Based on studies at
the time of this case, the mean incubation period for COVID-19 following exposure is 5.6-6.7
days.7 A meta-analysis of 32 studies published
in November 2020, found that the highest
percentage of virus detection from reverse
transcription polymerase chain reaction occurs
during days 0-4 of symptom onset.8 Though
limited data exists regarding the COVID-19
post-exposure incubation period for neonates,
these findings may suggest that the twins’
positive 24-hour nasopharyngeal swabs indicate exposure prior to delivery.
It appears vertical transmission may be possible with COVID-19 infection, and a meta-analysis has demonstrated that infection rates
of 3.2% are similar to those of other vertically-transmitted diseases.13 Further research into
the characteristics and potential mechanisms
for SARS-CoV-2 vertical transmission is warranted to better understand the risk of adverse
neonatal outcomes, including preterm delivery
and stillbirth, in pregnant patients with severe
COVID-1914 and asymptomatic COVID-19.15
Ascertaining evidence of vertical transmission in early trimesters may be difficult, since
COVID-19 IgG antibodies could be of maternal origin, and IgM antibodies (which do not
cross the placenta) decrease 15-28 days after

recovery.16 Additionally, there is evidence that
production of fetal IgM does not occur until approximately twenty weeks gestation.18 Though
preliminary studies indicate that severe cases
of neonatal COVID-19 are rare, future studies
may need to explore whether vertical transmission has an effect on the severity of the infection and the incidence of adverse long-term
outcomes.19,20 In general, data are currently limited regarding general maternal and neonatal
outcomes following first- or second-trimester
SARS-CoV-2 infection.17
Such adverse neonatal outcomes are further
compounded by the risk of increased maternal COVID-19 severity in pregnancy, including
venous thromboembolism, maternal death,
and need for ICU admission.14 In non-pregnant
patients, severe COVID-19 has been associated with coagulopathy and elevated D-dimer
levels,21 both of which are inherently increased
in pregnancy. However, D-dimer levels can be
elevated in pregnancy, providing limited utility
in reliably excluding venous thromboembolism,
and, therefore, are not recommended for use in
pregnancy.22,23 At the time of this case, venous
thromboembolism prophylaxis was not recommended in pregnancy; beginning December 17,
2020, prophylaxis was recommended for pregnant patients with severe COVID-19.24

Conclusion

The findings from this case suggest the risk of
adverse outcomes of a pregnancy complicated
by maternal SARS-CoV-2 infection and the potential for exposure to fetuses in utero as well
as long-term sequelae of neonatal SARS-CoV-2
infection. Further investigation of the pathophysiology of vertical transmission and longitudinal studies of developmental outcomes of neonates exposed to SARS-CoV-2 are warranted.
Since pregnant women have known increased
susceptibility to COVID-19 and increased risk of
adverse outcomes following infection, preventative measures to limit exposure through
social distancing and the COVID-19 mRNA vaccine, which has been shown to transfer maternal IgG to fetuses, should be encouraged.1,25
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